Tweets
@RheumNow on Social Media:
✧ virtual learning is the future of medicine
✧use digital strategies to filter good data online- AI can help focus interests & stay up to date - ex. Consensus or Feedly!
✧ peer to peer learning through social media enhances learning
#ACR25 https://t.co/n6MzhYoz0n
Kailey Singh @doctorkails ( View Tweet )
2 months 3 weeks ago
NEREA registry study on mortality in progressive pulmonary fibrosis in SARD-ILD. 158 patients. Median survival 7.8 years. DMARD use associated improved mortality. @RheumNow #ACR25 Abstr#1024 https://t.co/rK1caGi2r4
Richard Conway @RichardPAConway ( View Tweet )
2 months 3 weeks ago
Eat #fibre helps #rheumatoid #arthritis!
#RCT #RA w #MTX
Adding #super fibre
Mean #DAS28 3.8
7TJC, SJC2
Small N +RCT
Super fibre group
⬆️ #EULAR response
✅ improve #TH17 &TREG response
🤷♀️ tolerability and ease to use dietary super fibre
#ACR25 @RheumNow @ACRheum abst#LB15 https://t.co/ME6bsj4Ec7
Links:
Janet Pope @Janetbirdope ( View Tweet )
2 months 3 weeks ago
ADA-biosimilar use surged just before CVS formulary change then dropped sharply after. In RISE data, uptake reached 25% of users overall. Formulary policies reshape prescribing, but sustaining adoption needs alignment with patient access and preferences.
@RheumNow #ACR25 A#1042
Jiha Lee @JihaRheum ( View Tweet )
2 months 3 weeks ago
A post-hoc analysis from the ReFlaP study showed that there was a significant correlation between PsAID12 & HAQ scores
MDA-PsAIDrem (SN 82.6% SP97.1%) and MDA-PsAIDlow (SN 90.7% SP 91.2%)
Potential alternative for HAQ in MDA criteria?
#ACR25 @RheumNow Abs1411 https://t.co/QAxKsuhtDq
Links:
sheila @RHEUMarampa ( View Tweet )
2 months 3 weeks ago
In high-risk psoriasis patients with nail disease, Secukinumab reduced PsA onset over 5 years with a total exposure of 1022 patient-years. Annual incidence dropped from 2.7 to 0.49 per 100 patient-years. Data from the real world SERENA study. Abstract 1463 @RheumNow #ACR25
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
2 months 3 weeks ago
In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising.
@EBRheum asked what I knew/hoped he’d ask: why did this happen?
PJP is v rare in GCA
(https://t.co/oPN0dpvG8Q) & with MTX in other diseases.
Worth interrogation!
#ACR25 ABST0891 @RheumNow https://t.co/rsbScryIFR
Links:
David Liew @drdavidliew ( View Tweet )
2 months 3 weeks ago
POETYK-PsA 1 & 2 Phase 3 RCT TYK2i Deucravacitinib
Pooled analysis 640+pts PBO vs. 640+pts DEUCRA 6mg QD
MDA 12% vs 22%
All elements of MDA response sig different except for Leeds enthesitis index
DAPSA Remission 2% vs. 9%
PsARC 42% vs. 61%
PASDAS -1 vs. -1.7
mCPDAI -1.2 vs. -1.9 https://t.co/OTOFxTOrRp
Links:
Aurelie Najm @AurelieRheumo ( View Tweet )
2 months 3 weeks ago
Many GLP-1 drugs in the pipeline for management in #OA
#ACR25 @rheumnow https://t.co/y3UCp0CcUb
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
Semaglitide did help in weight loss and decrease in pain in knee OA
https://t.co/240sR5An3m
#acr25 @rheumnow
Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5
Links:
Bella Mehta @bella_mehta ( View Tweet )
2 months 3 weeks ago
GLP-1 receptor agonists reduce mortality in PsA
Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not
After propensity matching, those treated with GLP-1:
- lower risk MACE
- lower risk overall death
@RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
2 months 3 weeks ago
Is MTX worth anything in GCA?
METOGiA: MTX 52w vs TCZ 52w for GCA
MTX didn’t achieve non-inferiority to TCZ, but:
- clearly it does something
- continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC
#ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ
Links:
David Liew @drdavidliew ( View Tweet )
2 months 3 weeks ago
